Canada markets closed

Thiogenesis Therapeutics, Corp. (TTI.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.72000.0000 (0.00%)
At close: 03:09PM EDT
Currency in CAD

Valuation Measures4

Market Cap (intraday) 32.76M
Enterprise Value 29.43M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)9.73
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -131.12

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 32.86%
S&P500 52-Week Change 323.10%
52 Week High 31.0600
52 Week Low 30.6000
50-Day Moving Average 30.7810
200-Day Moving Average 30.7658

Share Statistics

Avg Vol (3 month) 310.6k
Avg Vol (10 day) 39.71k
Shares Outstanding 545.5M
Implied Shares Outstanding 645.5M
Float 831.03M
% Held by Insiders 119.04%
% Held by Institutions 11.05%
Shares Short (Apr 15, 2024) 42.86k
Short Ratio (Apr 15, 2024) 40.12
Short % of Float (Apr 15, 2024) 4N/A
Short % of Shares Outstanding (Apr 15, 2024) 40.00%
Shares Short (prior month Mar 15, 2024) 4203

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-48.08%
Return on Equity (ttm)-87.95%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-5.06M
Diluted EPS (ttm)-0.0100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)7.08M
Total Cash Per Share (mrq)0.18
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)4.23
Book Value Per Share (mrq)0.14

Cash Flow Statement

Operating Cash Flow (ttm)-3.25M
Levered Free Cash Flow (ttm)-1.92M